← Back to Search

Vitamin

Nicotinamide riboside for COVID-19 (NIRVANA Trial)

Phase 2
Waitlist Available
Led By Kumar Sharma, MD
Research Sponsored by The University of Texas Health Science Center at San Antonio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Provision of signed and dated informed consent form from a participant or legally authorized representative (LAR)
Male or female, >18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days to 90 days
Awards & highlights

NIRVANA Trial Summary

This trial will use NR to see if it can help improve NAD+ levels in people with COVID-19 and acute kidney injury. They will also be looking at the safety of using NR.

Eligible Conditions
  • COVID-19
  • Acute Kidney Injury

NIRVANA Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

NIRVANA Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days to 90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days to 90 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Whole Blood NAD+ Level
Number of Participants With Adverse Events of Grade 3 or Higher
Occurrence of Thrombocytopenia
Secondary outcome measures
Change in Area Under the Curve (AUC)
Change in Estimated Glomerular Filtration Rate (eGFR)
Change in Proteinuria
+1 more

NIRVANA Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Nicotinamide Riboside GroupExperimental Treatment1 Intervention
Nicotinamide riboside 250mg capsules will be administered 2 capsules twice daily for 10 days
Group II: Placebo GroupPlacebo Group1 Intervention
Placebo capsules will be administered 2 capsules twice daily for 10 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nicotinamide riboside
2021
Completed Phase 3
~400

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center at San AntonioLead Sponsor
450 Previous Clinical Trials
87,233 Total Patients Enrolled
4 Trials studying COVID-19
353 Patients Enrolled for COVID-19
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,338 Previous Clinical Trials
4,314,171 Total Patients Enrolled
4 Trials studying COVID-19
5,918 Patients Enrolled for COVID-19
Kumar Sharma, MD4.229 ReviewsPrincipal Investigator - UT Health San Antonio
Medical School - Armed Forces Medical College, Bachelor of Medicine, Bachelor of Surgery
Prince George's Hospital Center, Residency in Surgery
1Patient Review
I found his behaviour to be inappropriate and unprofessional. He made sexual advances and hugged me at the end of the appointment.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the ultimate objective of this research endeavor?

"This trial, lasting 10 days from the Baseline measurement, is targeting a Change in whole blood NAD+ level. Additional objectives include measuring changes to AUC serum creatinine over this period of time, Proteinuria at 30-90 days post randomization and eGFR also at 30-90 days post randomization."

Answered by AI

Has Nicotinamide riboside received regulatory clearance from the FDA?

"The safety of Nicotinamide riboside was provisionally rated a 2, as there is some evidence in favour of its security profile but no proof yet that it works."

Answered by AI

Are there any prior experiments with Nicotinamide riboside that have yielded noteworthy results?

"Presently, there are 23 clinical trials for Nicotinamide riboside that have commenced. Of these active studies, 3 of them fall into the Phase 3 category. Most experiments take place in Philadelphia; however, 26 different sites across the country host their own research initiatives related to this medication."

Answered by AI

Are participants in this study still being recruited?

"According to the information stored on clinicaltrials.gov, this particular trial is currently not open for recruitment. Initially posted on June 11th 2021 and lastly updated October 25th 2022, it has since been superseded by 1188 other medical studies actively requesting participants."

Answered by AI

What is the aggregate quantity of individuals engaging in this clinical experiment?

"Unfortunately, no new participants are being accepted into this trial at present. The posting of the study was first noted on June 11th 2021 and it has been updated most recently on October 25 2022. If you require further information about other clinical trials, there are currently 1165 studies recruiting for acute kidney injury and 23 involving Nicotinamide riboside seeking out patients."

Answered by AI
~7 spots leftby Mar 2025